BioSpace News Archive

Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), today announced that Boughey Distribution (“Boughey”), one of the United Kingdom’s leading logistics providers to the food industry, has selected the on-the-spot fingerprint test from the Company’s subsidiary, Intelligent Fingerprinting, to support its random drug screening program, replacing its previous urine-based test.

Neuron23™ Inc. today announced that the Company recently initiated dosing in a Phase 1 clinical trial of NEU-723 for the treatment of Parkinson’s disease.

LevitasBio, Inc., a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.

Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.

Onconova Therapeutics, Inc. today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

Orchestra BioMed Holdings, Inc. announced the addition of several highly accomplished industry veterans to its senior leadership team.

Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.

BrickBio has overcome previous limitations in unnatural amino acid driven site-specific conjugation by achieving stable, mammalian cell lines 5x faster than previous leaders in the space with 7x enhanced production.

Mirion Technologies, Inc. (NYSE: MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at Citi’s 2023 Global Industrial Tech and Mobility Conference in Miami, FL. The presentation will begin at 1:50 PM ET on Tuesday, February 21, 2023.